An ERRγ inverse agonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

GSK5182

Item No. 19097

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
δZ-[[4-[2-(dimethylamino)ethoxy]phenyl](4-hydroxyphenyl)methylene]-benzenebutanol
CAS Number
877387-37-6
Molecular Formula
C27H31NO3
Formula Weight
417.5
Purity
≥95%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/mlEthanol: Slightly soluble: 0.1-1 mg/ml
SMILES
OC1=CC=C(/C(C2=CC=C(OCCN(C)C)C=C2)=C(CCCO)/C3=CC=CC=C3)C=C1
InChi Code
InChI=1S/C27H31NO3/c1-28(2)18-20-31-25-16-12-23(13-17-25)27(22-10-14-24(30)15-11-22)26(9-6-19-29)21-7-4-3-5-8-21/h3-5,7-8,10-17,29-30H,6,9,18-20H2,1-2H3/b27-26-
InChi Key
ZVSFNBNLNLXEFQ-RQZHXJHFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $50

    Add

    5 mg

    $112

    Add

    10 mg

    $198

    Add

    25 mg

    $372

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    GSK5182 is an inverse agonist of estrogen-related receptor γ (ERRγ; IC50 = 77 nM in a reporter assay) and a derivative of (Z)-4-hydroxy tamoxifen (Item No. 14854).1 It selectively binds to ERRγ over ERα, ERRα, and ERRβ (IC50s = 0.11, 2, >10, and >10 µM, respectively). GSK5182 enhances radioiodine uptake and membrane localization of the sodium/iodide symporter (NIS) in BHT-101 and CAL-62 anaplastic thyroid cancer cells.2 It inhibits osteoclastogenesis induced by RANKL and macrophage colony-stimulating factor (M-CSF) in primary mouse bone marrow-derived macrophages (BMDMs) and induces apoptosis in osteoclasts when used at a concentration of 10 µM.3 GSK5182 (10 µM) inhibits fibrinogen secretion induced by the cannabinoid 1 (CB1) receptor agonist ACEA (arachidonoyl 2'-chloroethylamide; Item No. 91054) in AML12 hepatocytes.4 In vivo, GSK5182 (40 mg/kg) decreases blood glucose levels in a pyruvate tolerance test in a mouse model of high-fat diet-induced obesity.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kim, J., Song, J., Ji, H.D., et al. Discovery of potent, selective, and orally bioavailable estrogen-related receptor-γ inverse agonists to restore the sodium iodide symporter function in anaplastic thyroid cancer. J. Med. Chem. 62(4), 1837-1858 (2019).

    2. Singh, T.D., Jeong, S.Y., Lee, S.W., et al. Inverse agonist of estrogen-related receptor γ enhances sodium iodide symporter function through mitogen-activated protein kinase signaling in anaplastic thyroid cancer cells. J. Nucl. Med. 56(11), 1690-1696 (2015).

    3. Kim, H.J., Yoon, H.J., Lee, D.K., et al. The estrogen-related receptor γ modulator, GSK5182, inhibits osteoclast differentiation and accelerates osteoclast apoptosis. BMB Rep. 54(5), 266-271 (2021).

    4. Zhang, Y., Kim, D.K., Jung, Y.S., et al. Inverse agonist of ERRγ reduces cannabinoid receptor type 1-mediated induction of fibrinogen synthesis in mice with a high-fat diet-intoxicated liver. Arch. Toxicol. 92(9), 2885-2896 (2018).

    5. Kim, D.K., Gang, G.T., Ryu, D., et al. Inverse agonist of nuclear receptor ERRγ mediates antidiabetic effect through inhibition of hepatic gluconeogenesis. Diabetes 62(9), 3093-3102 (2013).